<?xml version="1.0" encoding="utf-8"?>
<oembed>
  <version>1</version>
  <type>rich</type>
  <provider_name>Libsyn</provider_name>
  <provider_url>https://www.libsyn.com</provider_url>
  <height>90</height>
  <width>600</width>
  <title>ORBITA-2 &amp;amp; PCI In Older Adults; Smartwatches and AFib Detection; Improved Management and Treatment of HF and HFrFF</title>
  <description> In this week’s View, Dr. Eagle looks at&amp;amp;nbsp;the ORBITA-2 trial&amp;amp;nbsp;and how&amp;amp;nbsp;percutaneous coronary intervention&amp;amp;nbsp;(PCI)&amp;amp;nbsp;may lead to greater&amp;amp;nbsp;symptom relief in older adults. He then explores the EQUAL&amp;amp;nbsp;trial&amp;amp;nbsp;that investigated&amp;amp;nbsp;how&amp;amp;nbsp;Apple&amp;amp;nbsp;smartwatch monitoring improves&amp;amp;nbsp;atrial fibrillation&amp;amp;nbsp;(AFib)&amp;amp;nbsp;detection.&amp;amp;nbsp;Finally, Dr. Eagle&amp;amp;nbsp;examines&amp;amp;nbsp;revelations&amp;amp;nbsp;from the EMPEROR-Preserved trial&amp;amp;nbsp;regarding&amp;amp;nbsp;interaction&amp;amp;nbsp;between&amp;amp;nbsp;SGLT2 inhibitors&amp;amp;nbsp;and&amp;amp;nbsp;baseline&amp;amp;nbsp;magnesium&amp;amp;nbsp;levels in&amp;amp;nbsp;treating&amp;amp;nbsp;patients&amp;amp;nbsp;who have either&amp;amp;nbsp;heart failure (HF)&amp;amp;nbsp;or&amp;amp;nbsp;HF with preserved&amp;amp;nbsp;ejection fraction (HFpEF).&amp;amp;nbsp;    Subscribe to Eagle’s Eye View  &amp;amp;nbsp;  </description>
  <author_name>Eagle's Eye View: Your Weekly CV Update From ACC.org</author_name>
  <author_url>http://www.acc.org</author_url>
  <html>&lt;iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/39981550/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen&gt;&lt;/iframe&gt;</html>
  <thumbnail_url>https://assets.libsyn.com/secure/content/198191490</thumbnail_url>
</oembed>
